Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
08 janv. 2024 07h30 HE
|
Arbutus Biopharma Corporation
Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other compounds expected in 2024 Initiation of a...
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
09 nov. 2023 16h01 HE
|
Arbutus Biopharma Corporation
The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline Preliminary data in subset of patients given imdusiran and then...
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
09 nov. 2023 07h01 HE
|
HOOKIPA Pharma Inc.
Reported positive preliminary Phase 2 data on additional patients for HB-200 in combination with pembrolizumab in the 1st-line setting for advanced HPV16+ head and neck cancer; data reinforce strong...
HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences
18 oct. 2023 07h01 HE
|
HOOKIPA Pharma Inc.
HB-400, a novel arenaviral therapeutic vaccine, generates robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical settingA Gilead-led Phase 1 clinical trial to...
Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
12 oct. 2023 16h05 HE
|
Vir Biotechnology, Inc.
Vir Biotechnology is participating in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference on Wednesday, October 25th
Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business development
21 sept. 2023 07h55 HE
|
Bluejay Therapeutics
SAN MATEO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc. a private clinical stage biopharmaceutical company focused on viral and liver diseases, today announced the...
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D
24 juin 2023 05h30 HE
|
Vir Biotechnology, Inc.
– Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an antiviral with an immunomodulator can achieve rapid and deep declines in...
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody
21 juin 2023 07h30 HE
|
Arbutus Biopharma Corporation
Evaluating safety and efficacy of combining AB-729, VTP-300, nucleos(t)ide analogues and nivolumab (Opdivo®) WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation...
Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023
21 juin 2023 02h01 HE
|
Arbutus Biopharma Corporation
Treatment was generally well tolerated with continued HBsAg declines in some patients WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or...
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023
07 juin 2023 02h13 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that five abstracts highlighting new data from the Company’s broad hepatitis portfolio...